[Renal hematoma after extracorporeal shockwave lithotripsy in a series of 324 consecutive sessions with the DOLI-S lithotripter: incidents, characteristrics, multifactorial analysis and review].
Archivos espanoles de urologia · 2008 · Vol. 61 · Issue 8 · 889-914
Academy Summary
This prospective observational study examined the incidence, clinical behaviour, risk factors, and evolution of renal haematoma following shock wave lithotripsy using the DOLI-S lithotripter.
The investigators evaluated 314 patients undergoing 324 renal SWL sessions. Post-treatment assessment included clinical examination, laboratory testing, and renal ultrasound, with CT used selectively when ultrasound findings were uncertain.
Renal haematoma was detected after 13% of treatments, substantially higher than rates reported in studies identifying only clinically apparent bleeding. However, more than half of the detected haematomas were asymptomatic. Symptomatic haematoma occurred after 6.2% of treatments, while progressive haematoma occurred after 2.16%. Blood transfusion was required after approximately 0.92% of SWL sessions.
The study identified multiple factors statistically associated with haematoma formation or progression, including higher shock-wave exposure, greater total energy, peri-procedural hypertension, pre-treatment microhaematuria, cystine stones, multiple stones treated during the same session, certain calyceal locations, liver disease, and exposure to antiplatelet or anti-inflammatory medications.
Importantly, haematoma progression or clinical presentation could occur during the first five days after SWL, even when the patient appeared stable during the first 24 hours. Larger haematomas, particularly those measuring approximately 4 cm or more on initial ultrasound, were more likely to progress.
Comments & Discussion0 comments
Discuss the publication's evidence, limitations and practical relevance. Please do not include identifiable patient information or individual medical advice.
No comments yet. Start the discussion.
Please log in to join the discussion.
